Tourette syndrome is a neurological condition that has no cure but can be managed with various strategies—some of which are ...

Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from ...

Relmada has acquired complete ownership rights to Sepranolone, developed for Tourette syndrome (TS) from Asarina Pharma.

Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...

Tourette syndrome is currently diagnosed about three times more frequently in males than in females. A new study finds that female individuals are less likely to be diagnosed with the syndrome, take ...

There's a big stigma surrounding Tourette syndrome and other brain disorders, but Milan teacher Larry Biederman is working to break ...

Winnipegger Orion Remoquillo has made living with Tourette syndrome his "superpower." A new short video shows how the teen has pushed himself in school, volunteering and work.

Tourette syndrome (TS ... Misunderstanding of the nature and possible causes of tics, their association with other disorders and particularly with stress, and the current media attention focused ...

CORAL GABLES, Fla. - Relmada Therapeutics , Inc. (NASDAQ:RLMD), a clinical-stage biotechnology firm with a market capitalization of $11.5 million, has announced the acquisition of Sepranolone, a Phase ...

The 22-year-old, who suffers from Tourette syndrome, is opening up ... dealing with the neurodevelopmental disorder characterized by rapid and repetitive tics and sounds, with her more than ...

Relmada Therapeutics (RLMD) announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid, from Asarina Pharma AB, being developed ...